迄今为止，还没有依从性评估工具来在开始口服溶瘤药物之前识别不依从性的风险。国家社区肿瘤配药协会组建了一个工作组，其任务是创建一个工具来满足这一需求。工具结构是在审查文献后定义的，确定了遵守的主要障碍。进行了第二次文献检索，以从经过验证的依从性问卷中找出针对特定障碍的问题。一旦最终草案完成，风险评估工具就会被内置到电子调查中，其中可以自动计算患者的风险类别。影响口服溶瘤药物依从性的六个最有影响力的因素被确定为患者的信心、健康素养、对治疗的看法。治疗、生活质量、社会支持和化疗方案的复杂性。创建了一份包含 6 个项目的调查问卷，其中包含 5 个针对患者的问题和 1 个针对临床医生的问题。提供了示例和描述，供临床医生在对治疗方案的复杂性进行分类时考虑。该工具旨在通过 10 分系统对每个问题的回答进行索引分类。结果将分为低、中或高不依从风险。对于开始口服溶瘤药物的患者来说，创建一种在开始治疗之前预测不依从性的工具是一个未满足的需求。该工具的目的是满足这些需求，并更好地指导临床医生为患者提供更好地管理不依从性的策略。下一步包括工具验证和临床实践试点。

To date, there is no adherence estimator to identify risk of nonadherence prior to initiating oral oncolytics.A workgroup was assembled through the National Community Oncology Dispensing Association and tasked with creating a tool to meet this need. Tool constructs were defined after a review of the literature identifying top barriers to adherence. A second literature search was conducted to identify questions targeting specific barriers from validated adherence questionnaires. Once a finalized draft was complete, the risk assessment tool was built into an electronic survey where a risk category can be automatically calculated for the patient.The six most impactful factors affecting compliance to oral oncolytics were identified as patient's confidence, health literacy, perception of treatment, quality of life, social support, and complexity of chemotherapy regimen. A six-item questionnaire was created with five patient-directed questions and one clinician-directed question. Examples and descriptions were provided for clinicians to consider when categorizing complexity of a regimen. The tool was designed for responses to each question to be indexed into categories through a 10-point system. Results will be stratified into low, moderate, or high risk for nonadherence.The creation of a tool to predict nonadherence prior to starting therapy is an unmet need for patients initiating oral oncolytics. The aim of this tool is to meet those needs and better guide clinicians to provide patients with strategies to better manage nonadherence. Next steps include tool validation and piloting in clinical practice.